1. Articles from ptca.org

  2. 1-24 of 24
    1. Glenn vs. The Volcano

      Glenn vs. The Volcano

      Today saw a "volley across the bow" between Volcano Corporation (Nasdaq: VOLC), a major manufacturer of IVUS, FFR and iFR technologies, and Engaged Capital LLC, an investment firm which holds over two million shares, or 5.1%, of Volcano stock. Engaged founder Glenn W. Welling sent a letter to Volcano demanding that the company begin a search for a new CEO and find a buyer for the company (press release printed below). The letter was prompted by the fact that Volcano's stock price has dropped by more than half over the past year. Engaged has been in discussions with ...

      Read Full Article
    2. Medtronic Enters the FFR and IVUS Technology Field With ACIST Co-Promotion

      Medtronic Enters the FFR and IVUS Technology Field With ACIST Co-Promotion

      Today Medtronic, Inc. (NYSE: MDT) and ACIST Medical Systems, Inc., a Bracco Group company, announced a strategic agreement to bring ACIST's FFR and IVUS products into U.S. cath labs. This collaboration marks the first time a major stent manufacturer will offer both FFR and IVUS technologies. FFR (Fractional Flow Reserve) is a functional measurement system, used to help determine whether or not stenting a blockage will provide benefit to the patient. The efficacy of FFR has been proven over many clinical trials such as FAME and FAME II. IVUS (IntraVascular UltraSound) is an imaging modality, which can be ...

      Read Full Article
    3. Best Uses from SCAI for Intravascular Ultrasound, Fractional Flow Reserve and

      Best Uses from SCAI for Intravascular Ultrasound, Fractional Flow Reserve and

      This morning the Society for Cardiovascular Angiography and Interventions (SCAI) issued a guidance document for the use of three major intra-coronary diagnostic tools for use in stenting and angioplasty. Published in the society's journal, Catheterization and Cardiovascular Interventions , the document details the best use of intravascular Ultrasound (IVUS), Fractional Flow Reserve (FFR) and Optical Coherence Tomography (OCT) as they relate to the diagnosis and optimal placements of stents. For years we at Angioplasty.Org have been urging more widespread use of these technologies, and detailed descriptions of these imaging and functional measurement modalities can be read in our Intravascular ...

      Read Full Article
    4. Laser Wars: Volcano Vindicated on OCT Trade Secret Suit

      Laser Wars: Volcano Vindicated on OCT Trade Secret Suit
      Last week the Superior Court of Massachusetts entered a Final Judgment in the latest round of "Laser Wars" being waged between Volcano Corporation (NASDAQ: VOLC) and St. Jude Medical (NYSE: STJ). Both companies "lasered up" a few years ago...and that has led to their "lawyering up" -- remember "Stent Wars"? In fact, Dr. Julio Palmaz, co-inventor of the first angioplasty balloon exandable Palmaz-Schatz stent, told me last year that the biggest thing an inventor needed to understand was just how much time he'll be spending in court, defending his patent. That certainly is the case with the laser technology ...
      Read Full Article
    5. OCT Wars: St. Jude Versus the Volcano

      OCT Wars: St. Jude Versus the Volcano
      Optical Coherence Tomography (OCT) is an exciting new imaging technique that is being used to assess the interior anatomy of coronary arteries during and after angioplasty and stent placement. (Read our exclusive interview with Dr. Giulio Guagliumi for more information about how OCT can aid in measuring the healing of stents.) This technology is just now beginning to bridge the divide between research tool and clinical aide -- for example, OCT can show high resolution pictures of stent struts and show whether they are covered or not. So the future for OCT imaging is definitely of major interest. The OCT market ...
      Read Full Article
    6. Volcano Corporation Schedules Second Quarter Conference Call, Webcast

      Volcano Corporation Schedules Second Quarter Conference Call, Webcast
      July 20, 2010 -- San Diego -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the second quarter and first six months of fiscal 2010 on Friday, July 30.
      Read Full Article
    7. Stent Helpers: IVUS, OCT and FFR -- Intravascular Tools At EuroPCR

      Stent Helpers: IVUS, OCT and FFR -- Intravascular Tools At EuroPCR
      This graphic shows three intravascular imaging/therapeutic modalities that were making news this month, both in the U.S. and in Paris at the EuroPCR meeting ending tomorrow. Clockwise they are Optical Coherence Tomography (OCT), Intravascular Ultrasound (IVUS) and Fractional Flow Reserve (FFR). You can read more about these in depth in Angioplasty.Org's Intravascular Imaging Center. Briefly, OCT and IVUS are ways of imaging the inside of a coronary artery during a standard invasive catheterization or angioplasty. Both of these imaging technologies can help the cardiologist see things not visible on standard X-ray angiography (an angiogram is essentially ...
      Read Full Article
    8. Volcano Corporation Presentation at Bank of America Merrill Lynch Health Care Conference to Be Webcast

      Volcano Corporation Presentation at Bank of America Merrill Lynch Health Care Conference to Be Webcast
      Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, said today that it will be participating in the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 11. The presentation by Scott Huennekens, president and chief executive officer, will begin at 9:20 a.m., Eastern Daylight Time (6:20 a.m., Pacific Daylight Time).
      Read Full Article
    9. Volcano Announces Activities at the ACC 2010

      March 11, 2010 -- San Diego -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today its participation in the Annual Scientific Sessions of the American College of Cardiology (ACC) Conference from March 14th to March 16th in Atlanta, GA. "The Percutaneous Coronary Intervention (PCI) procedures that benefit from our technology are very complex, often involving multi-vessel disease, bifurcations, left mains, chronic total occlusions, intermediate lesions, or various combinations," commented Joe Burnett, Executive Vice President at Volcano. "Our message, however, is ...
      Read Full Article
    10. Functional Measurement Functioning Well at Volcano

      Functional Measurement Functioning Well at Volcano
      To stent or not to stent? The question is more than a rhetorical one when a patient is on the cath lab table and a coronary blockage is seen on the angiogram. Luckily, there are methods available to help give a more scientific answer to this question. Equipment for two of these techniques, Intravascular Ultrasound (IVUS) and Fractional Flow Reserve (FFR -- a.k.a. "functional measurement") is manufactured by Volcano Corporation (Nasdaq: VOLC) a San Diego-based device company that announced its fourth quarter results earlier today.
      Read Full Article
    11. Volcano Has AAA Week: Accused, Approved and Acquired

      Volcano Has AAA Week: Accused, Approved and Acquired
      Volcano Corporation (Nasdaq: VOLC) has had a pretty interesting week. Last Thursday was the low point: a 13 person jury in Massachusetts Superior Court found Volcano and its subsidiary Axsun liable for a number of contractual breaches against LightLab Imaging, Inc. These all grew out of Volcano's purchase of Axsun, a company that had exclusive contracts with LightLab, Volcano's main competitor in the Optical Coherence Tomography (OCT) field. The court has set March 22 as the start of the damages assessment phase. But today, Volcano made two more positive announcements. The FDA has approved Volcano's latest IVUS ...
      Read Full Article
    12. Volcano Reports 22 Percent Increase in Third Quarter Revenues

      Volcano Reports 22 Percent Increase in Third Quarter Revenues
      Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacture and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today reported revenues of $53.9 million for the third quarter of fiscal 2009. The results for the quarter ended September 30, 2009, represent an increase of 22 percent over revenues of $44.1 million in the third quarter of 2008. Revenues for the third quarter of 2009 include $4.6 million from Axsun Technologies, Inc., which Volcano acquired at the end of 2008, and for which the company recorded no revenues in the third ...
      Read Full Article
    13. Volcano Corp. Announces Events at TCT Meeting

      Volcano Corp. Announces Events at TCT Meeting
      September 10, 2009 -- Volcano Corporation (Nasdaq: VOLC), a leader in the fields of Intravascular Ultrasound (IVUS) and Functional Measurement (FM) today announced a wide variety of events taking place at this year's Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco. A spectrum of activities will demonstrate how these technologies can improve the results obtained from angioplasty and stenting, and includes late-breaking clinical trials, symposia with panels of experts, live case demonstrations and an investor event. The main events are listed below. In addition, live case demonstrations utilizing IVUS and FM technology will be ongoing throughout the conference.
      Read Full Article
    14. Interview with Dr. Giulio Guagliumi on in the use of Optical Coherence Tomography (OCT) in the coronary arteries

      Interview with Dr. Giulio Guagliumi on in the use of Optical Coherence Tomography (OCT) in the coronary arteries
      Dr. Giulio Guagliumi, an internationally recognized leader in the use of Optical Coherence Tomography (OCT) in the coronary arteries, practices in the Cardiovascular Department of Ospedali Riuniti di Bergamo in Bergamo, Italy. He has spoken at numerous conferences worldwide and recently brought together experts for a course in Bergamo, titled "OCT, IVUS, FFR: When, Where, How" -- in which the clinical applications of these technologies were explored and demonstrated. Dr. Guagliumi has been published in numerous peer-reviewed journals and is principal investigator in several clinical trials assessing the performance of stents inside the coronary artery, using OCT imaging. One recent study ...
      Read Full Article
    15. Meeting to Highlight Use of New Imaging Technologies for Guiding Stent and Angioplasty Procedures

      Meeting to Highlight Use of New Imaging Technologies for Guiding Stent and Angioplasty Procedures
      This week marks one of the first courses to focus exclusively on the range of innovative intravascular imaging and measurement technologies that have been gaining in use over the past couple of years. "OCT, IVUS, FFR: When, Where, How" will be held on May 28 and 29 in Bergamo, Italy. The course will utilize the newest innovations in Optical Coherence Tomography (OCT), Intravascular Ultrasound (IVUS), Virtual Histology (VH) and Fractional Flow Reserve (FFR) and how they can be used to optimize percutaneous procedures, such as angioplasty and stenting.
      Read Full Article
    16. Optical Coherence Tomography (OCT) Presentations by Volcano at EuroPCR 2009

      Optical Coherence Tomography (OCT) Presentations by Volcano at EuroPCR 2009
      May 19, 2009 -- San Diego and Barcelona -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis of coronary and peripheral artery disease, today highlights its technology leadership position in the emerging field of Optical Coherence Tomography (OCT) at the EuroPCR conference in Barcelona, Spain.
      Read Full Article
    17. Effectiveness in Stenting (Stent Blog by Burt Cohen)

      Effectiveness in Stenting (Stent Blog by Burt Cohen)

      Aside from stents themselves, there's a whole toolbox of devices and techniques that are candidates for "comparative effectiveness" in that they may be able to increase the success of interventional procedures -- or even target patients who need these procedures more accurately. As Volcano Corp.'s CEO Scott Huennekens wrote in a recent Washington Times op-ed piece: The United States needs to focus on treating the right patient at the right time with the right method to lower health care costs, improve patient outcomes.

      Read Full Article
    18. Volcano Announces Schedule of Events at the ACC 2009, Integration into Indec and Medis Software Platforms

      Volcano Announces Schedule of Events at the ACC 2009, Integration into Indec and Medis Software Platforms
      March 27, 2009 -- San Diego -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced its presence at the 58th Annual Scientific Sessions of the American College of Cardiology (ACC) conference in Orlando, FL, to be held from March 29th to 31st, 2009. Joe Burnett, Vice President of Marketing at Volcano commented, "Three years ago, you could flip through the ACC program and see a couple of presentations on intravascular assessment using IVUS or FFR. This year, there are more than 50 presentations ...
      Read Full Article
    19. Abbott Moves Forward with Bioabsorbable Stent

      Abbott Moves Forward with Bioabsorbable Stent
      Abbott (NYSE: ABT) today announced that the first patient has been enrolled in phase two of the ABSORB clinical trial to assess the safety and efficacy of its novel bioabsorbable everolimus-eluting stent. Two year results of the original 30 patients were published earlier this month in The Lancet, showing reduction in plaque, zero stent thrombosis, no major cardiac events from six months to two years, successful absorption of the stent and restoration of vasomotion -- the ability of the coronary artery to contract and expand with normal pre-stent flexibility.
      Read Full Article
    20. ODESSA Trial Looks Inside Drug-Eluting Stents With Optical Coherence Tomography (OCT)

      ODESSA Trial Looks Inside Drug-Eluting Stents With Optical Coherence Tomography (OCT)
      October 20, 2008 / Washington, DC -- A new imaging technology, Optical Coherence Tomography (OCT) popped up in a number of presentations and evening symposia at this year's Transcatheter Cardiovascular Therapeutics meeting (TCT 2008). OCT is very new: one of the two currently available systems was first used in humans only five months ago. OCT image from ODESSA Trial, showing covered and uncovered struts of a drug-eluting stent OCT is a catheter-based system which provides a high resolution image of the inner artery surfaces (10 microns) and can easily show if stents have been covered by the body's endothelial cells ...
      Read Full Article
    21. Cordis Corporation Acquires LuMend, Inc.

      Warren, NJ (September 28, 2005) – Cordis Corporation, a Johnson & Johnson company, today announced the acquisition of LuMend, Inc., a privately held company focused on the development of chronic total occlusion (CTO) devices to treat peripheral vascular disease. A CTO is a complete or partial blockage of an artery that can lead to surgery or lower extremity amputation. Symptoms of an occlusion in the lower limbs, the most common location, are similar to other types of vessel blockages, and may include leg pain, limping, inability to walk and sores and infections that won't heal. Treatments for CTOs range from medication ...
      Read Full Article
    1-24 of 24
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks